S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Proceedings ArticleDOI
Abstract PD01-01: Cetuximab + Cisplatin in Estrogen Receptor-Negative, Progesterone Receptor-Negative, HER2-Negative (Triple-Negative) Metastatic Breast Cancer: Results of the Randomized Phase II BALI-1 Trial
J. Baselga,Salomon M. Stemmer,A Pego,Arlene Chan,J-C Goeminne,M-P Graas,J Kennedy,EM Ciruelos Gil,A. Zubel,J Groos,U Kia,Andreas Schneeweiss +11 more
TL;DR: Adding cetuximab to cisplatin increased the ORR compared with cis platin alone and significantly improved PFS in mTNBC, and adverse events were manageable and in line with what was expected from the different agents.
Journal ArticleDOI
MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells
Lihi Ninio-Many,Hadas Grossman,Mattan Levi,Sofia Zilber,Ilan Tsarfaty,Noam Shomron,Anna Tuvar,Dana Chuderland,Salomon M. Stemmer,Irit Ben-Aharon,Ruth Shalgi +10 more
TL;DR: The role of miR-125a-3p in cellular pathways accounted for motility and migration of prostate cancer cells, probably through its regulation on Fyn expression and Fyn-downstream proteins is illustrated.
Journal ArticleDOI
Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC).
Gabriel N. Hortobagyi,Salomon M. Stemmer,Howard A. Burris,Yoon Sim Yap,Gabe S. Sonke,Shani Paluch-Shimon,Mario Campone,Katarína Petráková,Kimberly L. Blackwell,Eric P. Winer,Wolfgang Janni,Sunil Verma,Pierfranco Conte,Carlos L. Arteaga,David Cameron,Fengjuan Xuan,M. Miller,C. Germa,Samit Hirawat,Joyce O'Shaughnessy +19 more
TL;DR: In this article, the authors reported updated efficacy and safety data from MONALEESA-2 with a further ~11 months of follow-up, showing that ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in patients with HR+, HER2-ABC.
Journal ArticleDOI
Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1-Mediated Secretion of Extracellular Vesicles.
Nil Grunberg,Meirav Pevsner-Fischer,Tal Goshen-Lago,Judith Diment,Yaniv Stein,Hagar Lavon,Shimrit Mayer,Oshrat Levi-Galibov,Gil Friedman,Yifat Ofir-Birin,LiJyun Syu,Cristina Migliore,Eyal Shimoni,Salomon M. Stemmer,Baruch Brenner,Andrzej A. Dlugosz,David Lyden,Neta Regev-Rudzki,Irit Ben-Aharon,Ruth Scherz-Shouval +19 more
TL;DR: In this paper, a stromal gene signature was associated with poor disease outcome, and the transcription factor heat shock factor 1 (HSF1) regulated the signature HSF1 upregulated inhibin subunit beta A (INHBA) and thrombospondin 2 (THBS2), which were secreted in CAF-derived extracellular vesicles (EV) to promote cancer.
Journal ArticleDOI
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer
Stephen R. D. Johnston,Henry L. Gomez,Salomon M. Stemmer,Maria Richie,Michael Durante,Lini Pandite,Vicki L. Goodman,Dennis J. Slamon +7 more
TL;DR: The combination of lapatinib plus pazopanib did not improve PDR compared with Lapatinib monotherapy, although RR was increased and toxicity was higher with the combination.